Zoetis (ZTS) Stock
Global animal health leader for pets and livestock. Here's the price, business snapshot, and what's worth knowing about Zoetis in July 2026.
Zoetis Inc. (ZTS) is a global leader in animal health, developing, manufacturing and commercialising medicines, vaccines and diagnostics for livestock and companion animals. With a market capitalisation of about $64.7bn, the company benefits from steady, recurring demand driven by pet ownership trends, livestock productivity needs and veterinary services growth across developed and emerging markets. Zoetis' strength lies in a diversified product portfolio, a broad geographic footprint and ongoing investment in R&D and targeted acquisitions to expand its pipeline. Investors should note potential advantages — predictable cash flows, margin resilience and dividend capacity — alongside risks such as regulatory scrutiny, pricing pressures, disease outbreaks and currency exposure. Zoetis may suit investors seeking exposure to defensive growth within healthcare, but it is important to assess valuation, portfolio fit and risk tolerance. This information is educational only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future returns.
Why It’s Moving
Zoetis Stock Gains Momentum as Analysts Project 29% Upside Following Strong Sector Trends and Earnings Momentum
- Healthcare sector momentum is bolstering Zoetis stock, with analysts highlighting strong demand for veterinary and pharmaceutical products as a key growth driver.
- Recent earnings reports signaled resilience, reinforcing investor confidence in Zoetis's ability to navigate market challenges and expand its product portfolio.
- Analysts emphasize that the stock's projected upside stems from a combination of stable revenue streams and strategic investments in emerging animal health technologies.
Zoetis Stock Gains Momentum as Analysts Project 29% Upside Following Strong Sector Trends and Earnings Momentum
- Healthcare sector momentum is bolstering Zoetis stock, with analysts highlighting strong demand for veterinary and pharmaceutical products as a key growth driver.
- Recent earnings reports signaled resilience, reinforcing investor confidence in Zoetis's ability to navigate market challenges and expand its product portfolio.
- Analysts emphasize that the stock's projected upside stems from a combination of stable revenue streams and strategic investments in emerging animal health technologies.
When is the next earnings date for ZOETIS INC (ZTS)?
Zoetis (ZTS) is expected to release its next earnings report on August 6, 2026, before the market opens. This upcoming release will cover the company's financial results for the second quarter of 2026. Historically, ZTS follows a regular schedule of releasing quarterly earnings in early May and early August, consistent with this projected date. Investors should monitor official company announcements for any potential adjustments to this timeline.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Zoetis stock, with a target price suggesting substantial growth potential.
Financial Health
Zoetis Inc is performing well with strong profits and cash flow, indicating robust financial stability.
Dividend
Zoetis Inc's dividend yield of 2.28% is reasonable for investors seeking dividends. If you invested $1000 you would be paid $22.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring ZTS
Next-Gen Proteins
Looking to invest in the future of food? This carefully selected group of stocks represents companies solving our global protein challenges. From plant-based alternatives to agricultural innovation, these stocks have been thoughtfully chosen by our analysts for their potential in this growing market.
Published: 17 June 2025
Explore BasketPets Are Family
The emotional bond with our furry companions has created a powerful, recession-resistant market. These carefully selected companies provide essential veterinary care, nutrition, and wellness services that pet owners prioritize regardless of economic conditions.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady demand drivers
Rising pet ownership and livestock productivity needs can support predictable revenue, though sales can vary with animal health trends and outbreaks.
Global footprint
A wide geographic reach exposes Zoetis to growth in emerging markets, but also brings currency and regulatory risk across regions.
R&D and pipeline
Ongoing investment in R&D and selective acquisitions fuels future products, yet new launches carry execution and approval risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
